This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
brca1
BRCA1
Tumor suppressor with RING-BRCT architecture; BARD1 heterodimer confers E3 ubiquitin ligase activity for homologous recombination (HR). Germline mutations: 70% lifetime breast and 40% ovarian cancer risk. Loss creates PARP inhibitor (olaparib) synthetic lethality.
Entry Metadata
| Field | Value |
|---|---|
| ID | brca1 |
| Name | BRCA1 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71. · PubMed 7545954
- Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2012;12(1):68-78. · PubMed 22193408
- Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533. · PubMed 28578601